Logo

Althea Wins $912K Contract to Develop Plasmid-Based HIV Vaccine for NIAD

Aug 29, 2006
NEW YORK (GenomeWeb News) – Althea Technologies said today that Advanced BioScience Laboratories has awarded it a cGMP manufacturing contract worth $911,549 to produce a DNA-based HIV-1 vaccine.
 
The multi-year contract is under a master agreement with the US National Institutes of Health and funded by the National Institute of Allergy and Infectious Diseases, Althea said.
 
It will “support Althea's efforts for plasmid DNA process development, vaccine production, purification, and regulatory documentation,” the company said in a statement.
 
Terms of the deal call for Althea to support a “larger vaccine development program” that is in conjunction with the South African AIDS Vaccine Initiative.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.